$6250 | Single User
$12500 | Site License
$18750 | Enterprise License

Acute Renal Failure (ARF) (Acute Kidney Injury) - Market Insight, Epidemiology and Market Forecast - 2027 [Report Updated: 14-02-2018]

Published by Delve Insight: 14 Feb 2018 | 201720 | In Stock

Introduction

DelveInsight's "Acute Renal Failure (ARF) (Acute Kidney Injury) - Market Insight, Epidemiology and Market Forecast - 2027" report provides a detailed analysis of the Acute Renal Failure (ARF) (Acute Kidney Injury) epidemiology and market outlook for the 7MM.

Markets Covered

• United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2016-2027

Acute Renal Failure (ARF) (Acute Kidney Injury) Understanding and Treatment Algorithm

The market report provides the overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Acute Renal Failure (ARF) (Acute Kidney Injury) Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2018 to 2027 segmented by seven major markets, enabling to understand the potential of the Acute Renal Failure (ARF) (Acute Kidney Injury) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Acute Renal Failure (ARF) (Acute Kidney Injury) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Acute Renal Failure (ARF) (Acute Kidney Injury) Market Outlook

The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Acute Renal Failure (ARF) (Acute Kidney Injury) market.

Acute Renal Failure (ARF) (Acute Kidney Injury) Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2027. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Acute Renal Failure (ARF) (Acute Kidney Injury) Report Insights

• Patient Population in Acute Renal Failure (ARF) (Acute Kidney Injury)

• Therapeutic Approaches in Acute Renal Failure (ARF) (Acute Kidney Injury)

• Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Analysis

• Acute Renal Failure (ARF) (Acute Kidney Injury) Market Size and Trends

• Acute Renal Failure (ARF) (Acute Kidney Injury) Market Opportunities

• Impact of upcoming Therapies in Acute Renal Failure (ARF) (Acute Kidney Injury)

Acute Renal Failure (ARF) (Acute Kidney Injury) Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition

Acute Renal Failure (ARF) (Acute Kidney Injury) Report Assessment

• Current Treatment Practices in Acute Renal Failure (ARF) (Acute Kidney Injury)

• Unmet Needs in Acute Renal Failure (ARF) (Acute Kidney Injury)

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• The report will help to develop Business Strategies by understanding the trends shaping and driving the Acute Renal Failure (ARF) (Acute Kidney Injury) market

• Organize sales and marketing efforts by identifying the best opportunities for Acute Renal Failure (ARF) (Acute Kidney Injury) market

• To understand the future market competition in the Acute Renal Failure (ARF) (Acute Kidney Injury) market.

Table of Contents
for Acute Renal Failure (ARF) (Acute Kidney Injury) - Market Insight, Epidemiology and Market Forecast - 2027 [Report Updated: 14-02-2018]

  • 1. Report Introduction

    2. Acute Renal Failure (ARF) (Acute Kidney Injury) Market Overview at a Glance

    2.1. Market Share Distribution of Acute Renal Failure (ARF) (Acute Kidney Injury) in 2017

    2.2. Market Share Distribution of Acute Renal Failure (ARF) (Acute Kidney Injury) in 2027

    3. Disease Background and Overview: Acute Renal Failure (ARF) (Acute Kidney Injury)

    3.1. Introduction

    3.2. Symptoms

    3.3. Etiology

    3.4. Risk Factors

    3.5. Pathophysiology

    3.6. Diagnosis

    3.7. Treatment

    4. Epidemiology and Patient Population

    4.1. Key Findings

    4.2. Total Prevalent/ Incident Patient Population of Acute Renal Failure (ARF) (Acute Kidney Injury) in 7MM

    4.3. Total Prevalent Patient Population of Acute Renal Failure (ARF) (Acute Kidney Injury) in 7MM – By Countries

    5. Epidemiology of Acute Renal Failure (ARF) (Acute Kidney Injury) by Countries

    5.1. United States

    5.1.1. Assumptions and Rationale

    5.1.2. Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    5.1.3. Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) *

    5.1.4. Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) *

    5.1.5. Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    5.1.6. Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    5.2. EU5

    5.3. Assumptions and Rationale

    5.4. Germany

    5.4.1. Assumptions and Rationale

    5.4.2. Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    5.4.3. Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) *

    5.4.4. Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) *

    5.4.5. Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    5.4.6. Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    5.5. France

    5.5.1. Assumptions and Rationale

    5.5.2. Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    5.5.3. Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) *

    5.5.4. Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) *

    5.5.5. Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    5.5.6. Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    5.6. Italy

    5.6.1. Assumptions and Rationale

    5.6.2. Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    5.6.3. Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) *

    5.6.4. Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) *

    5.6.5. Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    5.6.6. Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    5.7. Spain

    5.7.1. Assumptions and Rationale

    5.7.2. Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    5.7.3. Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) *

    5.7.4. Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) *

    5.7.5. Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    5.7.6. Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    5.8. United Kingdom

    5.8.1. Assumptions and Rationale

    5.8.2. Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    5.8.3. Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) *

    5.8.4. Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) *

    5.8.5. Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    5.8.6. Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    5.9. Japan

    5.9.1. Assumptions and Rationale

    5.9.2. Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    5.9.3. Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) *

    5.9.4. Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) *

    5.9.5. Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    5.9.6. Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    6. Current Treatment & Medical practices

    6.1. Treatment Algorithm

    6.2. Treatment Guidelines

    7. Unmet Needs of the Acute Renal Failure (ARF) (Acute Kidney Injury)

    8. Marketed Therapies

    8.1. Drug A: Company 1

    8.1.1. Drug Description

    8.1.2. Mechanism of Action

    8.1.3. Regulatory Milestones

    8.1.4. Advantages & Disadvantages

    8.1.5. Product Profile

    8.2. Drug B: Company 2

    8.2.1. Drug Description

    8.2.2. Mechanism of Action

    8.2.3. Regulatory Milestones

    8.2.4. Advantages & Disadvantages

    8.2.5. Product Profile

    9. Pipeline Therapies – At a glance

    10. Key Cross Competition

    11. Emerging Therapies for Acute Renal Failure (ARF) (Acute Kidney Injury)

    11.1. Drug C: Company 3

    11.1.1. Drug Description

    11.1.2. Clinical Trials Details

    11.1.3. Safety and Efficacy Profile

    11.1.4. Advantages & Disadvantages

    11.1.5. Pipeline Development Activities

    11.1.6. Product Profile

    11.2. Drug D: Company 4

    11.2.1. Drug Description

    11.2.2. Clinical Trials Details

    11.2.3. Safety and Efficacy Profile

    11.2.4. Advantages & Disadvantages

    11.2.5. Pipeline Development Activities

    11.2.6. Product Profile

    12. Acute Renal Failure (ARF) (Acute Kidney Injury) : 7MM Market Analysis

    12.1. 7MM Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury)

    12.2. 7MM Percentage Share of drugs marketed for Acute Renal Failure (ARF) (Acute Kidney Injury)

    12.3. 7MM Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Products

    13. Acute Renal Failure (ARF) (Acute Kidney Injury) : Country-Wise Market Analysis

    13.1. United States

    13.1.1. Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in United States

    13.1.2. Percentage Share of drugs marketed for Acute Renal Failure (ARF) (Acute Kidney Injury) in United States

    13.1.3. Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Products in United States

    13.1.4. Analysis of Upcoming Therapies and their Impact on the Market

    13.2. EU-5

    13.2.1. Germany

    13.2.1.1. Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in Germany

    13.2.1.2. Percentage Share of drugs marketed for Acute Renal Failure (ARF) (Acute Kidney Injury) in Germany

    13.2.1.3. Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Products in Germany

    13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market

    13.2.2. France

    13.2.2.1. Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in France

    13.2.2.2. Percentage Share of drugs marketed for Acute Renal Failure (ARF) (Acute Kidney Injury) in France

    13.2.2.3. Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Products in France

    13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market

    13.2.3. Italy

    13.2.3.1. Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in Italy

    13.2.3.2. Percentage Share of drugs marketed for Acute Renal Failure (ARF) (Acute Kidney Injury) in Italy

    13.2.3.3. Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Products in Italy

    13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market

    13.2.4. Spain

    13.2.4.1. Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in Spain

    13.2.4.2. Percentage Share of drugs marketed for Acute Renal Failure (ARF) (Acute Kidney Injury) in Spain

    13.2.4.3. Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Products in Spain

    13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market

    13.2.5. United Kingdom

    13.2.5.1. Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in United Kingdom

    13.2.5.2. Percentage Share of drugs marketed for Acute Renal Failure (ARF) (Acute Kidney Injury) in United Kingdom

    13.2.5.3. Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Products in United Kingdom

    13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market

    13.3. Japan

    13.3.1. Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in Japan

    13.3.2. Percentage Share of drugs marketed for Acute Renal Failure (ARF) (Acute Kidney Injury) in Japan

    13.3.3. Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Products in Japan

    13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

    14. Market Drivers

    15. Market Barriers

    16. Appendix

    17. Report Methodology

    17.1. Sources

    18. DelveInsight Capabilities

    19. Disclaimer

    20. About DelveInsight

    *Indication Specific

List Of Tables
in Acute Renal Failure (ARF) (Acute Kidney Injury) - Market Insight, Epidemiology and Market Forecast - 2027 [Report Updated: 14-02-2018]

Table 1: Total Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in 7MM

Table 2: Total Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in United States (2016-2027)

Table 4: Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in United States (2016-2027)

Table 5: Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in United States (2016-2027)

Table 6: Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in United States (2016-2027)

Table 7: Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in United States (2016-2027)

Table 8: Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Germany (2016-2027)

Table 9: Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Germany (2016-2027)

Table 10: Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Germany (2016-2027)

Table 11: Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Germany (2016-2027)

Table 12: Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Germany (2016-2027)

Table 13: Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in France (2016-2027)

Table 14: Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in France (2016-2027)

Table 15: Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in France (2016-2027)

Table 16: Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in France (2016-2027)

Table 17: Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in France (2016-2027)

Table 18: Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Italy (2016-2027)

Table 19: Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Italy (2016-2027)

Table 20: Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Italy (2016-2027)

Table 21: Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Italy (2016-2027)

Table 22: Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Italy (2016-2027)

Table 23: Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Spain (2016-2027)

Table 24: Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Spain (2016-2027)

Table 25: Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Spain (2016-2027)

Table 26: Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Spain (2016-2027)

Table 27: Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Spain (2016-2027)

Table 28: Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in UK (2016-2027)

Table 29: Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in UK (2016-2027)

Table 30: Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in UK (2016-2027)

Table 31: Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in UK (2016-2027)

Table 32: Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in UK (2016-2027)

Table 33: Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Japan (2016-2027)

Table 34: Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Japan (2016-2027)

Table 35: Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Japan (2016-2027)

Table 36: Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Japan (2016-2027)

Table 37: Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Japan (2016-2027)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in USD MM (2016-2027)

Table 42:7MM- Market Share Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Table 43:7MM- Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Table 44: United States-Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in USD MM (2016-2027)

Table 45: United States-Market Share Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Table 46: United States-Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Table 47: Germany-Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in USD MM (2016-2027)

Table 48: Germany-Market Share Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Table 49: Germany-Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Table 50: France-Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in USD MM (2016-2027)

Table 51: France-Market Share Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Table 52: France-Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Table 53: Italy-Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in USD MM (2016-2027)

Table 54: Italy-Market Share Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Table 55: Italy-Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Table 56: Spain-Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in USD MM (2016-2027)

Table 57: Spain-Market Share Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Table 58: Spain-Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Table 59:UK-Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in USD MM (2016-2027)

Table 60:UK-Market Share Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Table 61:UK-Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Table 62: Japan-Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in USD MM (2016-2027)

Table 63: Japan-Market Share Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Table 64: Japan-Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

List Of Figures, Charts and Diagrams
in Acute Renal Failure (ARF) (Acute Kidney Injury) - Market Insight, Epidemiology and Market Forecast - 2027 [Report Updated: 14-02-2018]

Figure 1: Total Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in 7MM

Figure 2: Total Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in United States (2016-2027)

Figure 4: Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in United States (2016-2027)

Figure 5: Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in United States (2016-2027)

Figure 6: Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in United States (2016-2027)

Figure 7: Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in United States (2016-2027)

Figure 8: Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Germany (2016-2027)

Figure 9: Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Germany (2016-2027)

Figure 10: Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Germany (2016-2027)

Figure 11: Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Germany (2016-2027)

Figure 12: Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Germany (2016-2027)

Figure 13: Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in France (2016-2027)

Figure 14: Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in France (2016-2027)

Figure 15: Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in France (2016-2027)

Figure 16: Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in France (2016-2027)

Figure 17: Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in France (2016-2027)

Figure 18: Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Italy (2016-2027)

Figure 19: Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Italy (2016-2027)

Figure 20: Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Italy (2016-2027)

Figure 21: Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Italy (2016-2027)

Figure 22: Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Italy (2016-2027)

Figure 23: Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Spain (2016-2027)

Figure 24: Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Spain (2016-2027)

Figure 25: Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Spain (2016-2027)

Figure 26: Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Spain (2016-2027)

Figure 27: Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Spain (2016-2027)

Figure 28: Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in UK (2016-2027)

Figure 29: Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in UK (2016-2027)

Figure 30: Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in UK (2016-2027)

Figure 31: Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in UK (2016-2027)

Figure 32: Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in UK (2016-2027)

Figure 33: Prevalent/Incident Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Japan (2016-2027)

Figure 34: Sub-Type Specific cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Japan (2016-2027)

Figure 35: Sex- Specific Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Japan (2016-2027)

Figure 36: Diagnosed Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Japan (2016-2027)

Figure 37: Treatable Cases of the Acute Renal Failure (ARF) (Acute Kidney Injury) in Japan (2016-2027)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in USD MM (2016-2027)

Figure 42:7MM- Market Share Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Figure 43:7MM- Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Figure 44: United States-Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in USD MM (2016-2027)

Figure 45: United States-Market Share Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Figure 46: United States-Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Figure 47: Germany-Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in USD MM (2016-2027)

Figure 48: Germany-Market Share Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Figure 49: Germany-Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Figure 50: France-Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in USD MM (2016-2027)

Figure 51: France-Market Share Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Figure 52: France-Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Figure 53: Italy-Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in USD MM (2016-2027)

Figure 54: Italy-Market Share Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Figure 55: Italy-Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Figure 56: Spain-Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in USD MM (2016-2027)

Figure 57: Spain-Market Share Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Figure 58: Spain-Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Figure 59:UK-Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in USD MM (2016-2027)

Figure 60:UK-Market Share Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Figure 61:UK-Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Figure 62: Japan-Market Size of Acute Renal Failure (ARF) (Acute Kidney Injury) in USD MM (2016-2027)

Figure 63: Japan-Market Share Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Figure 64: Japan-Market Sales of Acute Renal Failure (ARF) (Acute Kidney Injury) by Therapies in USD MM (2016-2027)

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

201720 | DIMI0021

Number of Pages

100

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Acute and Chronic Myelogenous Leukemia Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2016SummaryGlobal...
20 Apr 2016 by Global Data USD $2,500 More Info
Acute Pain Global Clinical Trials Review, H1, 2016
Acute Pain Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, “Acute ...
20 Apr 2016 by Global Data USD $2,500 More Info
Acute Respiratory Distress Syndrome Global Clinical Trials Review, H1, 2016
Acute Respiratory Distress Syndrome Global Clinical Trials Review, H1, 2016SummaryGlobalData's clini...
29 Feb 2016 by Global Data USD $2,500 More Info
Acute Stress Disorder Global Clinical Trials Review, H2, 2015
Acute Stress Disorder Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial repo...
16 Dec 2015 by Global Data USD $2,500 More Info
Acute Injury Global Clinical Trials Review, H2, 2015
Acute Injury Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report, “Acut...
09 Dec 2015 by Global Data USD $2,500 More Info
Acute Respiratory Failure Global Clinical Trials Review, H2, 2015
Acute Respiratory Failure Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial ...
25 Nov 2015 by Global Data USD $2,500 More Info
Acute and Sub-Acute Bursitis Global Clinical Trials Review, H2, 2015
Acute and Sub-Acute Bursitis Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical tri...
25 Nov 2015 by Global Data USD $2,500 More Info
Altitude Sickness (Acute mountain sickness) Global Clinical Trials Review, H2, 2015
Altitude Sickness (Acute mountain sickness) Global Clinical Trials Review, H2, 2015SummaryGlobalData...
25 Nov 2015 by Global Data USD $2,500 More Info
Acute Upper Respiratory Tract Infections Global Clinical Trials Review, H2, 2015
Acute Upper Respiratory Tract Infections Global Clinical Trials Review, H2, 2015SummaryGlobalData's ...
30 Oct 2015 by Global Data USD $2,500 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Download Free Report Summary PDF

Acute Renal Failure (ARF) (Acute Kidney Injury) - Market Insight, Epidemiology and Market Forecast - 2027 [Report Updated: 14-02-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data